Cleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%

MT Newswires Live

02/18

Cleo Diagnostics (ASX:COV) selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.

The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.

The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.

Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2612492145"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612492145\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612492145?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612492145","market":"fut","top_or_hot":-1,"title":"Cleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/COV.AU\">Cleo Diagnostics</a> (ASX:COV) selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.</p><p>The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.</p><p>The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.</p><p>Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-02-18 10:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/COV.AU\">Cleo Diagnostics</a> (ASX:COV) selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.</p><p>The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.</p><p>The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.</p><p>Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2612492145","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612492145","pubTimestamp":1771380745,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cleo Diagnostics  selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","BK4121":"生命科学工具和服务","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","COV.AU":"Cleo Diagnostics Ltd","TECH":"Techne Corporation","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Cleo Diagnostics选择Bio-Techne的平台作为卵巢癌血液检测的免疫测定仪器；股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":1.5,"COV.AU":1},"content_text":"Cleo Diagnostics (ASX:COV) selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}